PharmaCyte Biotech
PMCB
32 hedge funds and large institutions have $643K invested in PharmaCyte Biotech in 2026 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 4 closing their positions.
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
14% more funds holding
Funds holding: 28 → 32 (+4)
0.7% less ownership
Funds ownership: 9.71% → 9.01% (-0.7%)
10% less capital invested
Capital invested by funds: $712K → $643K (-$68.8K)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$99.3K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$54.9K |
| 3 |
VF
Virtu Financial
New York
|
+$28.7K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$21.4K |
| 5 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
+$8.82K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$121K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$72.4K |
| 3 |
Renaissance Technologies
New York
|
-$28.7K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$6.27K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$4.51K |
PMCB Hedge Fund Activity: Q1 2026 in Review
32 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in PharmaCyte Biotech (PMCB) for Q1 2026, worth a combined $643K — down 9.7% from $712K a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new PMCB positions and 4 closed out — a net gain of 5 holders — while 6 added to existing stakes and 7 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $99.3K. The largest seller was HRT Financial, cutting an estimated $121K.
- 32 institutional investors held PharmaCyte Biotech (PMCB) as of Q1 2026, up from 28 in Q4 2025.
- Funds reported $643K of PharmaCyte Biotech stock for Q1 2026, down 9.7% quarter-over-quarter.
- 9 funds opened new PharmaCyte Biotech positions in Q1 2026 and 4 closed out, a net change of +5 holders.
- The largest PharmaCyte Biotech buyer in Q1 2026 was Citadel Advisors, an estimated $99.3K added.
- The largest PharmaCyte Biotech seller in Q1 2026 was HRT Financial, an estimated $121K sold.
Based on aggregated 13F filings for Q1 2026.